GlassScriptPhysician profile
Brendan John Daly
NPI 1275731226
$2,713.79
in general payments reported to CMS, 2019-2025
17 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $89.76 · 2021: $278 · 2022: $279 · 2023: $380 · 2024: $817 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596 · Travel and Lodging: $34.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.69 |
| Travel and Lodging | $34.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $401.19 | 2019-2025 | |
| Abiomed | $345.99 | 2023-2025 | Impella |
| Heartflow, INC. | $340.88 | 2021-2025 | |
| Abbott Laboratories | $281.33 | 2019-2024 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $248.03 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $219.25 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $187.06 | 2020-2023 | Farxiga |
| Impulse Dynamics (USA) INC. | $158.19 | 2023-2024 | Optimizer, Optimizer |
| Amgen INC. | $127.80 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.75 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $95.64 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Kiniksa Pharmaceuticals International, Plc | $53.57 | 2024 | Arcalyst |
| Pfizer INC. | $45.18 | 2020-2023 | |
| Scpharmaceuticals INC. | $36.13 | 2025 | |
| Edwards Lifesciences Corporation | $27.67 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.88 | 2024 | Wegovy |
| Convatec INC. | $17.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.